Hepatic Cytochrome P450 Enzyme Alterations in Humans with Progressive Stages of Nonalcoholic Fatty Liver Disease
Open Access
- 3 August 2009
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Drug Metabolism and Disposition
- Vol. 37 (10), 2087-2094
- https://doi.org/10.1124/dmd.109.027466
Abstract
Members of the cytochrome P450 (P450) enzyme families CYP1, CYP2, and CYP3 are responsible for the metabolism of approximately 75% of all clinically relevant drugs. With the increased prevalence of nonalcoholic fatty liver disease (NAFLD), it is likely that patients with this disease represent an emerging population at significant risk for alterations in these important drug-metabolizing enzymes. The purpose of this study was to determine whether three progressive stages of human NALFD alter hepatic P450 expression and activity. Microsomes isolated from human liver samples diagnosed as normal, n = 20; steatosis, n = 11; nonalcoholic steatohepatitis (NASH) (fatty liver), n = 10; and NASH (no longer fatty), n = 11 were analyzed for P450 mRNA, protein, and enzyme activity. Microsomal CYP1A2, CYP2D6, and CYP2E1 mRNA levels were decreased with NAFLD progression, whereas CYP2A6, CYP2B6, and CYP2C9 mRNA expression increased. Microsomal protein expression of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 tended to decrease with NAFLD progression. Likewise, functional activity assays revealed decreasing trends in CYP1A2 (p = 0.001) and CYP2C19 (p = 0.05) enzymatic activity with increasing NAFLD severity. In contrast, activity of CYP2A6 (p = 0.001) and CYP2C9 (diclofenac, p = 0.0001; tolbutamide, p = 0.004) was significantly increased with NAFLD progression. Increased expression of proinflammatory cytokines tumor necrosis factor α and interleukin 1β was observed and may be responsible for observed decreases in respective P450 activity. Furthermore, elevated CYP2C9 activity during NAFLD progression correlated with elevated hypoxia-induced factor 1α expression in the later stages of NAFLD. These results suggest that significant and novel changes occur in hepatic P450 activity during progressive stages of NAFLD.Keywords
This publication has 44 references indexed in Scilit:
- Gender divergent expression of Nqo1 in Sprague Dawley and August Copenhagen x Irish ratsJournal of Biochemical and Molecular Toxicology, 2008
- Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitisLiver International, 2007
- Design and validation of a histological scoring system for nonalcoholic fatty liver diseaseJournal of Hepatology, 2005
- Polymorphisms of CYP2A6 and its practical consequencesBritish Journal of Clinical Pharmacology, 2001
- Overexpression of Cytochrome P-450 Isoforms Involved in Aflatoxin B1 Bioactivation in Human Liver with Cirrhosis and HepatitisToxicologic Pathology, 1996
- Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease*1, *2Journal of Hepatology, 1995
- Extrahepatic Metabolism of Drugs in HumansClinical Pharmacokinetics, 1994
- Comparison of Levels of Cytochromes P-450, CYP1A2, CYP2E1, and Their Related Monooxygenase Activities in Human Surgical Liver SamplesAlcohol: Clinical and Experimental Research, 1993
- The P450 Superfamily: Update on New Sequences, Gene Mapping, Accession Numbers, Early Trivial Names of Enzymes, and NomenclatureDNA and Cell Biology, 1993
- Spectroscopic quantitation of cytochrome P‐450 in human lung microsomesJournal of Biochemical Toxicology, 1990